Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
Table 1
Patient and tumor characteristics.
Characteristic
Study cohort
Control cohort
Gender, (%)
Male
9 (64.3)
4 (44.4)
Female
5 (35.7)
5 (55.6)
Age at diagnosis, years
Median (range)
57.5 (30–75)
58 (18–76)
Stage at diagnosis
Localized
10 (71.4)
9 (100)
Metastasized
4 (28.6)
0 (0)
Prior surgery
Yes
9 (64.3)
9 (100)
No
5 (35.7)
0 (0)
Prior radiation
Yes
9 (64.3)
8 (88.9)
No
5 (35.7)
1 (11.1)
Time to progression to metastatic disease, months
Median (range)
25.3 (5.0–119.6
12.6 (3.0–71.0)
At progression to metastatic disease†
Patients with a single metastatic site, (%)
5 (35.7)
6 (66.7)
Patients with multiple metastatic sites, (%)
9 (64.3)
3 (33.3)
Chemotherapy for metastatic disease
Yes
3 (21.4)‡
2 (22.2)
No
11 (78.6)
7 (77.8)
For patients presenting with localized disease. †At presentation of metastatic disease. ‡Prior to molecular profiling.
